Optimal Dosages for Melatonin Supplementation Therapy in Older Adults: A Systematic Review of Current Literature (original) (raw)

References

  1. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186–95.
    Article CAS PubMed Google Scholar
  2. Ibrahim MG, Bellomo R, Hart GK, Norman TR, Goldsmith D, Bates S, Egi M. A double-blind placebo-controlled randomised pilot study of nocturnal melatonin in tracheostomised patients. Crit Care Resusc. 2006;8(3):187–91.
    PubMed Google Scholar
  3. Lynch HJ, Wurtman RJ, Moskowitz MA, Archer MC, Ho MH. Daily rhythm in human urinary melatonin. Science. 1975;187(4172):169–71.
    Article CAS PubMed Google Scholar
  4. Waldhauser F, Weiszenbacher G, Tatzer E, Gisinger B, Waldhauser M, Schemper M, Frisch H. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab. 1988;66(3):648–52.
    Article CAS PubMed Google Scholar
  5. Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012;52(4):437–45.
    Article CAS PubMed Central PubMed Google Scholar
  6. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116(2):91–5.
    Article CAS PubMed Google Scholar
  7. Lushington K, Dawson D, Kennaway DJ, Lack L. The relationship between 6-sulphatoxymelatonin rhythm phase and age in self-reported good sleeping controls and sleep maintenance insomniacs aged 55–80 years. Psychopharmacology (Berl). 1999;147(1):111–2.
    Article CAS Google Scholar
  8. Haimov I, Laudon M, Zisapel N, Souroujon M, Nof D, Shlitner A, Herer P, Tzischinsky O, Lavie P. Sleep disorders and melatonin rhythms in elderly people. BMJ. 1994;309(6948):167.
    Article CAS PubMed Central PubMed Google Scholar
  9. Zeitzer JM, Duffy JF, Lockley SW, Dijk DJ, Czeisler CA. Plasma melatonin rhythms in young and older humans during sleep, sleep deprivation, and wake. Sleep. 2007;30(11):1437–43.
    PubMed Central PubMed Google Scholar
  10. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003;70(4):334–41.
    Article PubMed Google Scholar
  11. Peck JS, LeGoff DB, Ahmed I, Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psychiatry. 2004;12(4):432–6.
    PubMed Google Scholar
  12. De Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry. 2010;25(12):1201–8.
    Article PubMed Google Scholar
  13. Shigeta H, Yasui A, Nimura Y, Machida N, Kageyama M, Miura M, Menjo M, Ikeda K. Postoperative delirium and melatonin levels in elderly patients. Am J Surg. 2001;182(5):449–54.
    Article CAS PubMed Google Scholar
  14. Sultan SS. Assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly. Saudi J Anaesth. 2010;4(3):169–73.
    Article PubMed Central PubMed Google Scholar
  15. Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2011;26(7):687–94.
    Article PubMed Google Scholar
  16. Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2–4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19(5):423–31.
    CAS PubMed Google Scholar
  17. Dollins AB, Lynch HJ, Wurtman RJ, Deng MH, Kischka KU, Gleason RE, Lieberman HR. Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology (Berl). 1993;112(4):490–6.
    Article CAS Google Scholar
  18. Lewy AJ, Sack RL. Exogenous melatonin’s phase-shifting effects on the endogenous melatonin profile in sighted humans: a brief review and critique of the literature. J Biol Rhythms. 1997;12(6):588–94.
    Article CAS PubMed Google Scholar
  19. Lewy AJ, Bauer VK, Ahmed S, Thomas KH, Cutler NL, Singer CM, Moffit MT, Sack RL. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol Int. 1998;15(1):71–83.
    Article CAS PubMed Google Scholar
  20. Zaidan R, Geoffriau M, Brun J, Taillard J, Bureau C, Chazot G, Claustrat B. Melatonin is able to influence its secretion in humans: description of a phase-response curve. Neuroendocrinology. 1994;60(1):105–12.
    Article CAS PubMed Google Scholar
  21. Burgess HJ, Revell VL, Eastman CI. A three pulse phase response curve to three milligrams of melatonin in humans. J Physiol. 2008;586(2):639–47.
    Article CAS PubMed Central PubMed Google Scholar
  22. Burgess HJ, Revell VL, Molina TA, Eastman CI. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab. 2010;95(7):3325–31.
    Article CAS PubMed Central PubMed Google Scholar
  23. Arendt J, Bojkowski C, Folkard S, Franey C, Marks V, Minors D, Waterhouse J, Wever RA, Wildgruber C, Wright J. Some effects of melatonin and the control of its secretion in humans. Ciba Found Symp. 1985;117:266–83.
    CAS PubMed Google Scholar
  24. Nagtegaal JE, Kerkhof GA, Smits MG, Swart AC, Van Der Meer YG. Delayed sleep phase syndrome: a placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. J Sleep Res. 1998;7(2):135–43.
    Article CAS PubMed Google Scholar
  25. Braam W, van Geijlswijk I, Keijzer H, Smits MG, Didden R, Curfs LM. Loss of response to melatonin treatment is associated with slow melatonin metabolism. J Intellect Disabil Res. 2010;54(6):547–55.
    Article CAS PubMed Google Scholar
  26. Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol. 1985;19(4):517–21.
    Article CAS PubMed Central PubMed Google Scholar
  27. Mallo C, Zaidan R, Faure A, Brun J, Chazot G, Claustrat B. Effects of a four-day nocturnal melatonin treatment on the 24 h plasma melatonin, cortisol and prolactin profiles in humans. Acta Endocrinol (Copenh). 1988;119(4):474–80.
    CAS Google Scholar
  28. Mallo C, Zaĭdan R, Galy G, Vermeulen E, Brun J, Chazot G, Claustrat B. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol. 1990;38(3):297–301.
    Article CAS PubMed Google Scholar
  29. Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA. 1994;91(5):1824–8.
    Article CAS PubMed Central PubMed Google Scholar
  30. Van Den Heuvel CJ, Kennaway DJ, Dawson D. Effects of daytime melatonin infusion in young adults. Am J Physiol. 1998;275(1 Pt 1):E19–26.
    Google Scholar
  31. Zhdanova IV, Wurtman RJ, Balcioglu A, Kartashov AI, Lynch HJ. Endogenous melatonin levels and the fate of exogenous melatonin: age effects. J Gerontol A Biol Sci Med Sci. 1998;53(4):B293–8.
    Article CAS PubMed Google Scholar
  32. Shah J, Langmuir V, Gupta SK. Feasibility and functionality of OROS melatonin in healthy subjects. J Clin Pharmacol. 1999;39(6):606–12.
    Article CAS PubMed Google Scholar
  33. Nickkholgh A, Schneider H, Sobirey M, Venetz WP, Hinz U, le Pelzl H, Gotthardt DN, Cekauskas A, Manikas M, Mikalauskas S, Mikalauskene L, Bruns H, Zorn M, Weigand MA, Büchler MW, Schemmer P. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res. 2011;50(4):381–8.
    Article CAS PubMed Google Scholar
  34. Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care. 2008;12(2):R52.
    Article PubMed Central PubMed Google Scholar
  35. Dawson D, Rogers NL, van den Heuvel CJ, Kennaway DJ, Lushington K. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs. J Biol Rhythms. 1998;13(6):532–8.
    Article CAS PubMed Google Scholar
  36. Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007;47(4):485–96.
    Article CAS PubMed Google Scholar
  37. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep. 1998;21(1):52–68.
    CAS PubMed Google Scholar
  38. Kedziora-Kornatowska K, Szewczyk-Golec K, Czuczejko J, Pawluk H, van Marke de Lumen K, Kozakiewicz M, Bartosz G, Kedziora J. Antioxidative effects of melatonin administration in elderly primary essential hypertension patients. J Pineal Res. 2008;45(3):312–7.
    Article CAS PubMed Google Scholar
  39. Kedziora-Kornatowska K, Szewczyk-Golec K, Kozakiewicz M, Pawluk H, Czuczejko J, Kornatowski T, Bartosz G, Kedziora J. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res. 2009;46(3):333–7.
    Article CAS PubMed Google Scholar
  40. Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N. Prolonged-release melatonin for insomnia—an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag. 2011;7:301–11.
    CAS PubMed Central PubMed Google Scholar
  41. Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, Ruscica M, Dozio E, Esposti R, DeMartini G, Fraschini F, Rezzani R, Reiter RJ, Iapichino G. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res. 2010;48(2):142–7.
    Article CAS PubMed Google Scholar
  42. Sugaya K, Nishijima S, Miyazato M, Kadekawa K, Ogawa Y. Effects of melatonin and rilmazafone on nocturia in the elderly. J Int Med Res. 2007;35(5):685–91.
    Article CAS PubMed Google Scholar
  43. Van Marke de Lumen K, Kedziora-Kornatowska K, Czuczejko J, Szewczyk-Golec K, Pawluk H, Motyl J, Kornatowski T, Kedziora J. Time dependent effect of melatonin administration on lipid peroxidation, superoxide dismutase activity and melatonin concentration in the elderly patients with essential arterial hypertension. Przegl Lek. 2008;65(6):273–6.
    PubMed Google Scholar
  44. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86(10):4727–30.
    Article CAS PubMed Google Scholar
  45. Fourtillan JB, Brisson AM, Gobin P, Ingrand I, Decourt JP, Girault J. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm Drug Dispos. 2000;21(1):15–22.
    Article CAS PubMed Google Scholar
  46. Markantonis SL, Tsakalozou E, Paraskeva A, Staikou C, Fassoulaki A. Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers. J Clin Pharmacol. 2008;48(2):240–5.
    Article CAS PubMed Google Scholar
  47. Lewy AJ, Emens JS, Sack RL, Hasler BP, Bernert RA. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol Int. 2002;19(3):649–58.
    Article CAS PubMed Google Scholar

Download references